| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 |
Form 4: Loomis David K, VP, Chief Accounting Officer
Sold 232 shares ($1.48K) |
| 03 Nov 2026 | S-3 |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – |
| 28 Sep 2026 | S-8 |
| 22 Sep 2026 | 144 |
| 09 Sep 2026 | 144 |
| 04 Sep 2026 | 144 |
| 31 Aug 2026 | S-8 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 04 Aug 2026 | 144 |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – |
| 09 Jul 2026 | 144 |
| 26 Jun 2026 |
Form 4: Smaldone Alsup Laurie, Director
Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Norwalk Leslie V, Director
Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Morrison Briggs, Director
Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Kennedy Edward Moore Jr., Director
Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Cunningham Everett, Director
Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy) |
Loading...